China Archives | Page 2 of 54

Flexiv Closes Over 100M USD Series B Funding

Flexiv Ltd., a global general-purpose robotics company, closed an over 100m USD Series B funding round.

Vetreska Closes $20M Series B Financing

Vetreska, a Chinese pet lifestyle brand, closed a $20M Series B financing round.

Transcenta Completes $105M Crossover Financing

Transcenta Holding Limited, a global biotherapeutics company with integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, completed a 105m USD crossover financing.

ClassIn Raises $265M in Series C Funding

ClassIn, a Beijing, China-based EdTech company creator of an online interactive classroom, raised $265m in Series C funding.

AInnovation Closes Series C Financing

AInnovation, a Beijing, China-based artificial intelligence company, completed a Series C financing round of undisclosed amount.

dMed Closes US$100M Series C Financing

dMed, a Shangai, China-based clinical CRO, completed a US$100m Series C financing.

vesoft Raises $10M in Funding

vesoft Inc., a Hangzhou, China-based developer of the Nebula Graph™ database, raised an additional $10m in a series pre-A+ funding round.

Beacon Education Raises $6M in Series B Funding

Beacon Education, a Beijing-based provider of online degrees to China, closed a $6M Series B financing round.

Eluminex Biosciences Closes $50M Series A Financing

Eluminex Biosciences Limited, a Shangai, China-based ophthalmic biotechnology company, completed a $50m (USD) Series A financing.

IceKredit Raises $US33M in Series C1 Funding

IceKredit, a Shangai, China-based AI powered platform for business, closed a $33m series C1 round of funding.

Qiming’s Portfolio Company Antengene Lists on Main Board of HKEX

Clinical-stage Asia-Pacific biopharmaceutical company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited on Nov. 20, 2020.

Qiming Venture Partners Closes Fund VII, at US$ 1.2 Billion

Qiming Venture Partners, a Shangai, China-based venture capital firm, closed Qiming Venture Partners Fund VII, at $1.2 billion.

D3 Bio Raises US$200M in Series A Financing

D3 Bio, a Shangai, China-based global biotechnology company focused on developing and commercializing precision medicines to improve or replace existing standard-of-care treatments that do not fully meet patient needs, launched today with US$200m in Series A financing.